News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Federal Trade Commission is suing Hims & Hers alleging the telehealth platform shared users' health data with online advertisers despite promising privacy and engaged in deceptive billing and cancellation practices, an FTC spokesperson said. Hims & Hers is one of the largest telehealth players in the market for weight loss drugs.
The U.S. Federal Trade Commission sued Hims & Hers on Wednesday alleging the telehealth platform shared users' health data with online advertisers, despite promising privacy, and engaged in deceptive billing and cancellation practices. Hims & Hers stock added to losses after the news and was trading down around 12%. The company offers telehealth appointments and prescriptions for erectile dysfunction, hair loss, and mental health medications, which it ships straight to customers.
Hims & Hers Health Inc. is in the spotlight Friday after an FDA advisory panel voted Thursday to recommend four key peptides be added to a federal list that would allow compounding pharmacies to legally produce them. FDA Panel Splits,...
Quest Diagnostics put up a definitive beat Thursday, driven by solid demand across its consumer division, leading the stock to surge.
A cash-secured put on Hims & Hers stock is one way to potentially buy the stock for a discount or achieve a healthy return.
The deal adds telehealth operations in Australia, Canada and Japan.
Agilent Technologies (NYSE:A) raised its fiscal 2026 outlook after reporting stronger-than-expected second-quarter results, with management pointing to broad-based demand, instrument replacement momentum, pricing actions and operational gains from its Ignite operating system. CEO Padraig McDonnell
Hims & Hers Health (NYSE: HIMS) faces a demanding customer acquisition challenge to hit its 2026 revenue guidance amid rising churn risks tied to its oral Wegovy subscription model, Bank of America said. Analysts estimate HIMS would need to add approximately 225,000 new oral Wegovy...
Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.
By Sriparna Roy May 21 (Reuters) - Hims & Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a generic version of semaglutide, the active ingredient in Novo Nordisk's
Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the wreckage. But here’s what you should actually be watching. The Q1 2026 release on May 11, 2026 was a fracture. EPS came in ... Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead
Hims & Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the company's long-term profitability story.
June S&P 500 E-Mini futures (ESM26) are up +0.25%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.79% this morning, buoyed by gains in technology stocks, while investors gear up for crucial U.S. producer inflation data and the highly anticipated Trump-Xi summit.
Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi
Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting results this Monday after the bell. Here’s what to expect.
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.16%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.87%. June E-mini S&P futures (ESM26 ) fell -0.16%, and June E-mini Nasdaq futures...
HIMS reports an adjusted loss and a revenue miss in first-quarter 2026 as gross margin decreases, but it lifts its full-year revenue outlook.
Hims & Hers (NYSE:HIMS) reported first quarter financial results that included a wider-than-expected loss and softer revenue performance, sending shares down nearly 14% to about $25 on Tuesday morning. For the quarter, the telehealth company posted a net loss of $92.1 million, or $0.40...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.74%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.55%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.45%. June E-mini S&P futures (ESM26 ) are down -0.74%, and June E-mini Nasdaq futures...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.44%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.74%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.72%. June E-mini S&P futures (ESM26 ) are down -0.38%, and June E-mini Nasdaq futures...
Hims & Hers stock sinks as higher costs weighed on the health platform's quarterly results.
Hims & Hers stock sinks as higher costs weighed on the health platform's quarterly results.
The telehealth company posted a net loss of $92 million in the first quarter as its shift away from compounded weight loss drugs drove up costs
Despite restructuring costs, Hims & Hers Health Inc (HIMS) reports robust international growth and raises 2026 revenue outlook.
Hims & Hers Health (NYSE:HIMS) reported first-quarter 2026 revenue growth and raised its full-year revenue outlook, while executives said a strategic shift in the company’s weight-loss business is creating short-term margin pressure and volatility in GAAP results. On the company’s earnings call
By Amina Niasse and Siddhi Mahatole May 11 (Reuters) - Hims & Hers Health missed Wall Street estimates for first-quarter revenue and posted a surprise loss on Monday, as the telehealth company's shift
The telehealth platform posted a quarterly loss of $92.1 million, driven by higher expenses, including those tied to operations, technology and general and administrative functions.
Shares of Hims & Hers Health sank late Monday after the company underperformed first-quarter earnings and revenue expectations, surprising Wall Street with a quarterly loss. The telehealth provider, which made a name for itself in the business of weight-loss drugs, posted a first-quarter loss of 40 cents a share, compared with profit of 20 cents a share a year ago. Wall Street was looking for a profit of 3 cents a share.
